Mackenzie Financial Corp Buys 324,461 Shares of Agilent Technologies, Inc. $A

Key Points

• Mackenzie Financial Corp boosted its stake in Agilent by 52.8%, buying 324,461 shares to hold 938,670 shares (about 0.33% of the company) worth roughly $120.5 million.
• Q3 results and guidance: Agilent reported $1.36 EPS (missed by $0.01) and $1.80B revenue (up 7% YoY), and set FY2026 EPS guidance of 5.900–6.040 with Q2 guidance of 1.390–1.420.
• Strategic moves include a ~<$950 million acquisition of Biocare Medical and the launch of Agilent Advanced Therapeutics (CDMO), while analysts maintain a consensus "Moderate Buy" with an average price target near $161.20.

Mackenzie Financial Corp boosted its stake in shares of Agilent Technologies, Inc. (NYSE:A - Free Report) by 52.8% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 938,670 shares of the medical research company's stock after purchasing an additional 324,461 shares during the period. Mackenzie Financial Corp owned 0.33% of Agilent Technologies worth $120,478,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of the stock. Flynn Zito Capital Management LLC increased its position in shares of Agilent Technologies by 3.2% during the 3rd quarter. Flynn Zito Capital Management LLC now owns 2,257 shares of the medical research company's stock worth $290,000 after purchasing an additional 69 shares during the last quarter. Forum Financial Management LP boosted its holdings in shares of Agilent Technologies by 2.5% in the 3rd quarter. Forum Financial Management LP now owns 2,921 shares of the medical research company's stock valued at $375,000 after buying an additional 70 shares during the last quarter. Gabelli Funds LLC grew its stake in shares of Agilent Technologies by 1.1% in the third quarter. Gabelli Funds LLC now owns 6,620 shares of the medical research company's stock valued at $850,000 after buying an additional 74 shares in the last quarter. Wedmont Private Capital grew its stake in shares of Agilent Technologies by 2.3% in the third quarter. Wedmont Private Capital now owns 3,630 shares of the medical research company's stock valued at $503,000 after buying an additional 81 shares in the last quarter. Finally, waypoint wealth counsel increased its holdings in Agilent Technologies by 4.3% during the third quarter. waypoint wealth counsel now owns 1,984 shares of the medical research company's stock worth $255,000 after buying an additional 82 shares during the last quarter. 87.41% of the stock is currently owned by institutional investors.

Agilent Technologies Price Performance

Shares of NYSE A opened at $115.44 on Thursday. The firm has a market cap of $32.62 billion, a P/E ratio of 25.48, a price-to-earnings-growth ratio of 2.43 and a beta of 1.31. The company has a current ratio of 2.07, a quick ratio of 1.59 and a debt-to-equity ratio of 0.44. Agilent Technologies, Inc. has a 1-year low of $96.43 and a 1-year high of $160.27. The business's 50 day moving average is $131.36 and its 200-day moving average is $135.93.

Agilent Technologies (NYSE:A - Get Free Report) last released its quarterly earnings results on Wednesday, February 25th. The medical research company reported $1.36 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.37 by ($0.01). Agilent Technologies had a net margin of 18.26% and a return on equity of 24.49%. The firm had revenue of $1.80 billion during the quarter, compared to the consensus estimate of $1.81 billion. During the same quarter last year, the firm earned $1.31 earnings per share. The business's revenue for the quarter was up 7.0% compared to the same quarter last year. Agilent Technologies has set its FY 2026 guidance at 5.900-6.040 EPS and its Q2 2026 guidance at 1.390-1.420 EPS. Equities research analysts predict that Agilent Technologies, Inc. will post 5.58 earnings per share for the current year.

Agilent Technologies Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 22nd. Stockholders of record on Tuesday, March 31st will be given a $0.255 dividend. This represents a $1.02 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date of this dividend is Tuesday, March 31st. Agilent Technologies's payout ratio is presently 22.52%.

Agilent Technologies News Summary

Here are the key news stories impacting Agilent Technologies this week:

• Positive Sentiment: Agilent agreed to acquire Biocare Medical for about $950 million — a bolt-on that strengthens its immunohistochemistry/diagnostics consumables and pathology market exposure, adding recurring reagents and slide/staining workflow products that can lift revenue durability and margin profile over time. Agilent to acquire Biocare in $950M 'complementary combination'
• Positive Sentiment: Agilent launched “Agilent Advanced Therapeutics,” unifying its CDMO capabilities across the U.S. and Canada — a move aimed at scaling drug-development and manufacturing services that can generate higher-margin service revenue and cross-sell opportunities with instrument/consumable customers. Agilent Launches Agilent Advanced Therapeutics, Unifying CDMO Capabilities Across Canada and United States
• Neutral Sentiment: Citi opened a 90‑day “upside catalyst” watch on Agilent as part of a sector sweep — this flags potential positive catalysts but is not a formal upgrade; it signals analysts are watching for near‑term drivers rather than changing the fundamental view. Citi Flags Agilent Technologies, Cuts Icon PLC Target, and More
• Neutral Sentiment: Coverage noting “steady growth amid headwinds” emphasizes Agilent’s resilient top-line and reiterated FY26 guidance but highlights macro and sector pressures that could keep near-term multiples constrained. Agilent Technologies Signals Steady Growth Amid Headwinds
• Neutral Sentiment: Analysis pieces point out Agilent has recently underperformed the S&P 500 despite analyst optimism — a reminder that valuation and sector rotation dynamics could limit near-term upside. Is Agilent Technologies Stock Underperforming the S&P 500?
• Negative Sentiment: High-profile negative commentary from Jim Cramer — saying investors “don’t need” the stock — may pressure retail sentiment and contribute to short-term volatility despite the company’s strategic moves. Jim Cramer on Agilent Technologies: “I Don’t Think You Need It”

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. Barclays dropped their price target on shares of Agilent Technologies from $165.00 to $150.00 and set an "overweight" rating on the stock in a research report on Thursday, February 26th. Evercore upgraded shares of Agilent Technologies from an "in-line" rating to an "outperform" rating and boosted their price objective for the stock from $155.00 to $160.00 in a research note on Monday, January 5th. Wells Fargo & Company dropped their target price on shares of Agilent Technologies from $175.00 to $165.00 and set an "overweight" rating on the stock in a report on Thursday, February 26th. Weiss Ratings reiterated a "hold (c+)" rating on shares of Agilent Technologies in a research note on Monday, December 29th. Finally, The Goldman Sachs Group assumed coverage on Agilent Technologies in a report on Tuesday, December 9th. They set a "buy" rating and a $170.00 price target for the company. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and three have issued a Hold rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $161.20.

About Agilent Technologies

Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company's product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.

Founded as a corporate spin-off from Hewlett‑Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.

Want to see what other hedge funds are holding A? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agilent Technologies, Inc. (NYSE:A - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.